DNA-Probe Rapidly Screens for MRSA

It will aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.

The technology in the Detect-Ready kits provides a unique differential diagnosis engine that produces highly accurate results, minimizing false positives and false negatives. Samples for testing are simple to obtain using nasal swabs and the assay's ready-to-use premixed reagents require only the addition of patient sample to run the test.

Off-the-shelf room temperature-stabilized and requiring no refrigeration, Detect-Ready kits are compatible with multiple RT-PCR platforms found in clinical laboratories. This flexibility to leverage existing infrastructure and equipment to run Detect-Ready assays eliminates the need for additional hospital capital investment.

Molecular Detection Inc. (MDI; Wayne, PA, USA; and Jerusalem, Israel) and Inverness Medical Deutschland GmbH (Cologne, Germany) have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in Germany, Austria, and Switzerland.

MDI is a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis.

Inverness Medical Deutschland, a leading distributor of medical diagnostic products in European markets, is a subsidiary of Inverness Medical Innovations, Inc. a global market leader in point-of-care diagnostics.

Related Links:
Molecular Detection Inc.
Inverness Medical Deutschland GmbH
Inverness Medical Innovations, Inc.